Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 78 |
| Active Pipeline (Recruiting Now) | 35 (18) |
| Completed vs Stopped Early | 8 / 4 (5.1%) |
| Median Closed Actual Enrollment | 410 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 2 (2 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 8 |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 8 |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07038382 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection | Phase II | RECRUITING |
| NCT06839066 | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Thera | Phase II | RECRUITING |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastri | Phase III | RECRUITING |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage | Phase III | ACTIVE NOT RECRUITING |
| NCT05003245 | Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Henlius Biotech Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.